SEARCH

SEARCH BY CITATION

References

  • 1
    Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 150212.
  • 2
    Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 151320.
  • 3
    Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996; 14: 175664.
  • 4
    Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 1999; 17: 250613.
  • 5
    Berthold DR, Pond GR, Soban F, De Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 2008; 26: 2425.
  • 6
    Armstrong AJ, Garrett-Mayer ES, Yang YC, De Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 2007; 13: 6396403.
  • 7
    Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 55663.
  • 8
    Rosenberg JE, Ryan CJ, Weinberg VK et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J. Clin. Oncol. 2009; 27: 27728.
  • 9
    Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 2009; 27: 54318.
  • 10
    Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 2007; 25: 396570.
  • 11
    Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 2006; 98: 51621.
  • 12
    Hussain M, Goldman B, Tangen C et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 2009; 27: 24506.
  • 13
    Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 2008; 26: 114859.
  • 14
    Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J. Clin. Oncol. 2009; 27: 276671.
  • 15
    De Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008; 14: 63029.
  • 16
    Flaig TW, Tangen CM, Hussain MH et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J. Clin. Oncol. 2008; 26: 15326.
  • 17
    Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 113842.
  • 18
    Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 2007; 110: 124854.
  • 19
    Febbo PG, Richie JP, George DJ et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin. Cancer Res. 2005; 11: 523340.
  • 20
    Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J. Urol. 2008; 180: 56570.
  • 21
    Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 2005; 23: 825361.
  • 22
    Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 2009; 27: 37428.
  • 23
    Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 2008; 26: 456371.
  • 24
    Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 78790.
  • 25
    Scher HI, Beer T, Higano CS et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J. Clin. Oncol. 2009; 27 (15s): abstract 5011.
  • 26
    Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 2006; 24: 308994.
  • 27
    Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol. 2007; 25: 66974.
  • 28
    Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 36709.
  • 29
    Schellhammer PF, Higano C, Berger ER et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). Late Breaking Abstract 4, American Urological Association Annual Meeting 28 April 2009, Chicago, IL.
  • 30
    Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006; 107: 6774.
  • 31
    Higano CS, Corman JM, Smith DC et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113: 97584.
  • 32
    Small E, Demkow T, Gerritsen WR et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proceedings Genitourinary Cancer Symposium February 2009, Orlando, FL, abstract 7.
  • 33
    Gerritsen W, Van Den Eertwegh AJ, De Gruijl T et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J. Clin. Oncol. 2008; 26: abstract 5146.
  • 34
    Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2007; 13: 181015.
  • 35
    Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert. Opin. Investig. Drugs 2009; 18: 100111.
  • 36
    Kantoff PW, Schuetz T, Blumenstein BA et al. Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2009; 27 (15s): abstract 5013.
  • 37
    George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 2001; 7: 19326.
  • 38
    Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001; 61: 25336.
  • 39
    Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 2009 (Epub ahead of print).
  • 40
    Dror Michaelson M, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 2009; 20: 91320.
  • 41
    George DJ, Liu G, Wilding G et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) – preliminary results. J. Clin. Oncol. 2008; 26: abstract 5131.
  • 42
    Chi KN, Ellard SL, Hotte SJ et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann. Oncol. 2008; 19: 74651.
  • 43
    Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 2008; 14: 20914.
  • 44
    Steinbild S, Mross K, Frost A et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br. J. Cancer 2007; 97: 14805.
  • 45
    Carducci MA, Nelson JB, Bowling MK et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol. 2002; 20: 217180.
  • 46
    Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 195966.
  • 47
    James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur. Urol. 2009; 55: 111223.
  • 48
    Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 2004; 96: 87982.
  • 49
    Roodman GD. Mechanisms of bone metastasis. N. Engl. J. Med. 2004; 350: 165564.
  • 50
    Fizazi K, Yang J, Peleg S et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin. Cancer Res. 2003; 9: 258797.
  • 51
    Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 2009; 27: 156471.
  • 52
    Picus JHS, Halabi S, Rini B et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006. Proc. Am. Soc. Clin. Oncol. 2003; 22: 393; abstract 1578.
  • 53
    Ning YM, Arlen PM, Gulley JL et al. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castration-refractory prostate cancer (CRPC). J. Clin. Oncol. 2008; 26 (May 20 suppl): abstract 5000.
  • 54
    Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap – Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R. D. 2008; 9: 2619.
  • 55
    Ng SS, MacPherson GR, Gutschow M, Eger K, Figg WD. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin. Cancer Res. 2004; 10: 41927.
  • 56
    Figg WD, Dahut W, Duray P et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 2001; 7: 188893.
  • 57
    Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. 2004; 22: 25329.
  • 58
    Garcia JA, Cooney MM, Elson P et al. Clinical activity of ketoconazole and lenalidomide in castrated progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial. Genitourinary Cancer Symposium 2008, San Francisco, CA: abstract 27.
  • 59
    Petrylak DP, Resto-Garces K, Tibyan M et al. A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J. Clin. Oncol. 2009; 27 (15s): abstract 5156.
  • 60
    McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52: 69404.
  • 61
    Tolcher AW, Chi K, Kuhn J et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2005; 11: 385461.
  • 62
    Sternberg CN, Dumez H, Van Poppel H et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann. Oncol. 2009; 20: 12649.
  • 63
    MacVicar GR, Greco A, Reeves J et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC). J. Clin. Oncol. 2009; 27 (15s): abstract 5062.
  • 64
    Poiesz B, Reeves J, McNulty W et al. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. J. Clin. Oncol. 2009; 27 (15s): abstract 5145.
  • 65
    Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 2005; 23: 4591601.
  • 66
    Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 2004; 22: 252231.
  • 67
    Lara PN Jr, Chee KG, Longmate J et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004; 100: 212531.
  • 68
    De Bono JS, Bellmunt J, Attard G et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J. Clin. Oncol. 2007; 25: 25762.
  • 69
    Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 2007; 13: 583440.
  • 70
    Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 2007; 13: 5549s5555s.
  • 71
    Canil CM, Moore MJ, Winquist E et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 2005; 23: 45560.
  • 72
    Small EJ, Fontana J, Tannir N et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007; 100: 7659.
  • 73
    Gravis G, Bladou F, Salem N et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann. Oncol. 2008; 19: 16248.
  • 74
    Gross M, Higano C, Pantuck A et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007; 7: 142.
  • 75
    Whang YE, Moore CN, Armstrong AJ et al. A phase II trial of lapatinib in hormone refractory prostate cancer. J. Clin. Oncol. 2008; 26: abstract 16037.
  • 76
    Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res. 2009; 15: 35409.
  • 77
    Park SI, Zhang J, Phillips KA et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008; 68: 332333.
  • 78
    Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br. J. Cancer 2009; 101: 2638.
  • 79
    Yu EY, Wilding G, Posadas E et al. Dasatinib in patients with metastatic hormone-refractory (castration-resistant) progressive prostate cancer: a phase II study. J. Clin. Oncol. 2008; 26 (May 20 suppl): Abstract 5156.
  • 80
    Chi KN, Eisenhauer E, Fazli L et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 2005; 97: 128796.
  • 81
    Chi KN, Siu LL, Hirte H et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res. 2008; 14: 8339.
  • 82
    Chi KN, Hotte SJ, Yu E et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2009; 27 (15s): abstract 5012.
  • 83
    Saad F, Hotte SJ, North S et al. A phase II randomized study evaluating custirsen (OGX-011) in patients with hormone refractory prostate cancer (HRPC) who relapsed on or within 6 Months of first-line docetaxel therapy. J. Clin. Oncol. 2008; 26 (May 20 suppl): Abstract 5002.
  • 84
    Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005; 6: 392400.
  • 85
    Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63: 9405.
  • 86
    Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357: 33641.
  • 87
    Morris MJ, Pandit-Taskar N, Carrasquillo J et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J. Clin. Oncol. 2009; 27: 243642.
  • 88
    Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J. Clin. Oncol. 2009; 27: 331924.
  • 89
    Fizazi K, Beuzeboc P, Lumbroso J et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol. 2009; 27: 242935.
  • 90
    Getzenberg RH, Light BW, Lapco PE et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997; 50: 9991006.
  • 91
    Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol. 2003; 21: 1238.
  • 92
    Novacea Press Release. November 2007.
  • 93
    Carducci MA, Musib L, Kies MS et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol. 2006; 24: 40929.
  • 94
    Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005; 65: 282531.
  • 95
    Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008; 68: 86171.
  • 96
    Ramachandran K, Gopisetty G, Gordian E et al. Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009; 69: 152735.
  • 97
    Sonpavde G, Aparicio A, Zhan F et al. Azacitidine favorably impacts PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration resistant prostate cancer. Urol. Oncol. 2009 (Epub ahead of print).